» Articles » PMID: 2295112

Intracellular Concentrations of Anti Cancer Drugs in Leukemic Cells in Vitro Vs in Vivo

Overview
Specialty Oncology
Date 1990 Jan 1
PMID 2295112
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

A comparison of intracellular concentrations of daunorubicin, doxorubicin and ara-C in myeloid blast cells was carried out in vivo and in vitro. In vivo, blood samples were obtained from 27 patients with acute nonlymphoblastic leukemia during and up to 4 days after drug infusion. Leukemic cells were isolated and drug concentrations were determined by HPLC. Before treatment, leukemic cells from 21 patients were isolated from blood and bone marrow, and in vitro incubations were done with anthracyclines for 1-3 h at concentrations of 0.1-1.0 microM and with ara-C for 1 h to 5 days at concentrations of 0.5-5.0 microM. The cells were cultured for 5 days, during which cell samples were taken for drug determination. The results showed that incubation with 0.2 microM daunorubicin for 1 h and 0.2 microM doxorubicin for 3 h and continuous exposure to 0.5 microM ara-C gave intracellular concentration curves similar to those obtained in vivo. After 5 days' culture, the cytotoxic effect was determined by vital dye staining with fast green, the addition of an internal standard of fixed goose erythrocytes, cytospin centrifugation and counter-staining of living cells with haematoxylin/eosin (DiSC). Incubations at the above-mentioned concentrations exerted a cytotoxic effect of approximately 50%. We conclude that in mimicking the in vivo situation, it is important to consider differences in intracellular pharmacokinetics.

Citing Articles

A Flow Cytometric Clonogenic Assay Reveals the Single-Cell Potency of Doxorubicin.

Maass K, Kulkarni C, Quadir M, Hammond P, Betts A, Wittrup K J Pharm Sci. 2015; 104(12):4409-4416.

PMID: 26344409 PMC: 4706798. DOI: 10.1002/jps.24631.


Quantitation of cell-associated doxorubicin by high-performance liquid chromatography after enzymatic desequestration.

Andersen A, Warren D, Slordal L Cancer Chemother Pharmacol. 1994; 34(3):197-202.

PMID: 8004751 DOI: 10.1007/BF00685077.


Intracellular uptake and cytotoxic effect in vitro of doxorubicin and epirubicin in human leukemic and normal hematopoietic cells.

Tidefelt U, Sundman-Engberg B, Paul C Cancer Chemother Pharmacol. 1991; 29(1):7-12.

PMID: 1742852 DOI: 10.1007/BF00686328.

References
1.
Gale R, Cline M . High remission-induction rate in acute myeloid leukaemia. Lancet. 1977; 1(8010):497-9. DOI: 10.1016/s0140-6736(77)91366-6. View

2.
Baurain R, Zenebergh A, Trouet A . Cellular uptake and metabolism of daunorubicin as determined by high-performance liquid chromatography. Application to L1210 cells. J Chromatogr. 1978; 157:331-6. DOI: 10.1016/s0021-9673(00)92350-1. View

3.
Weisenthal L, Dill P, Finklestein J, Duarte T, Baker J, Moran E . Laboratory detection of primary and acquired drug resistance in human lymphatic neoplasms. Cancer Treat Rep. 1986; 70(11):1283-95. View

4.
Paul C, Liliemark J, Tidefelt U, Gahrton G, Peterson C . Pharmacokinetics of daunorubicin and doxorubicin in plasma and leukemic cells from patients with acute nonlymphoblastic leukemia. Ther Drug Monit. 1989; 11(2):140-8. DOI: 10.1097/00007691-198903000-00004. View

5.
Paul C, Peterson C, Gahrton G, Lockner D . Uptake of free and DNA-bound daunorubicin and doxorubicin into human leukemic cells. Cancer Chemother Pharmacol. 1979; 2(1):49-52. DOI: 10.1007/BF00253105. View